Tesaro reports Q2 EPS ($2.82), consensus ($2.49)
Reports Q2 revenue $29.46M, consensus $17.6M. Tesaro reported net product revenue of $28.8M, which included ZEJULA sales of $25.9M and VARUBI/VARUBY sales of $2.9M. "The U.S. launch of ZEJULA, the first and only PARP inhibitor to be approved for the maintenance treatment of women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker status, is off to an excellent start, and we are gratified by the positive feedback that we have received from patients and prescribers. Following its introduction in late April, ZEJULA quickly became the most frequently prescribed PARP inhibitor in the U.S. The MAA for ZEJULA is under review in Europe, and we are pleased that interest in our expanded access program has been high, as we anticipate the European launch of ZEJULA by year end," said CEO Lonnie Moulder.